65,437 trials
Coronary Artery Disease
Primary: RADIAL STRAIN — 0.158; 0.149; 0.150; 0.190 unitless (strain) — p=0.001
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28 (CRP)) at Week 12 — -1.26; -0.78; -2.46; -1.36 units on a scale — p=0.978
Migraine
Primary: Change From Baseline in Frequency of Headache Days — -3.12 days per 28-days — p=<0.001
Urinary Tract Infection (UTI) · Complicated Urinary Tract Infection · Pyelonephritis
Primary: Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC) — 80.7 Percentage of participants
Major Depressive Disorder
Primary: Recall of Cognitive Therapy Content — 25.4; 26.8; 24.7; 28.2 Number of correct units of information
Leukemia · Myelodysplastic Syndromes
Primary: PHASE I: Maximum Tolerated Dose of Azacitidine — 75 mg/m2 subcutaneously for 5 days
Leukemia
Primary: Overall Response Rate — 23; 31; 23 Participants
Intraocular Retinoblastoma
Primary: Group D Eyes - Treatment Failure Within One Year — 0.52 Probability of treatment failure
Chronic Hepatitis B
Primary: Proportion of Patients With HBsAg Response at 12 Week of Therapy — 0; 0; 1; 0 Participants
Influenza
Primary: Number of Participants With Adverse Events — 5; 8; 69; 30 Participants
Biliary Stricture
Primary: Feasibility of Imaging the Bile Duct With the OFDI Probe — 7 Participants
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 17; 5; 31; 30 Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-935 — 477.000; 1150.889; 1882.000 nanogram per milliliter (ng/mL) — p=0.079
Congestive Heart Failure · Emotions · Patient Compliance
Primary: Feasibility of the PP-based Health Behavior Intervention — 7.8 Exercises Completed
Advanced Breast Cancer
Primary: Progression Free Survival (PFS) Per Investigator Assessment — 20.5; 12.8 Months — p=0.00000041